Navigation Links
AfriCoLeish receives funding boost from European Union

[Geneva, Switzerland and Nairobi, Kenya 23 April 2013] - Research and development (R&D) project, AfriCoLeish, is supported by the European Union Seventh Framework Programme (EU FP7) through a grant of 3 million. The project will run for three years and aims to test new treatments for kala-azar (visceral leishmaniasis, or VL) and co-infection of the disease with HIV in Ethiopia and Sudan.

The AfricoLeish project, 'Care Package for Treatment and Control of Visceral Leishmaniasis in East Africa', aims to develop and deliver a shorter combination treatment for kala-azar patients that is equally as safe and effective as the current WHO-recommended first-line treatment for the disease (SSG&PM, sodium stibogluconate and paromomycin) in East Africa. The project also aims to determine appropriate treatment strategies for kala-azar in patients that are also HIV positive, in order to treat and also prevent repetitive relapses that are common in co-infected patients.

Kala-azar (VL) is fatal if left untreated. An estimated 300,000 cases occur per year in 70 endemic countries. Estimates suggest 30,000 new cases per year in Africa, with numbers rising sharply during an epidemic. Existing monotherapies are toxic, costly, and difficult to administer, and the treatment duration is long, requiring extended hospital stays. Efficacious and cost-effective treatments as well as prevention of relapse play a critical role in the reduction of disease reservoir, forming a vital part of disease control. In addition, co-infection of kala-azar and HIV is a growing problem and renders treatment more difficult for both diseases.

'While we have managed to deliver a new first-line treatment for kala-azar in East Africa, sodium stibogluconate combined with paromomycin, SSG&PM, we need to continue searching for shorter, safer treatments', said Dr Monique Wasunna, Head of DNDi Africa and one of the four principal investigators of the AfriCoLeish project. 'Through a randomized clinical trial in Eastern Africa, the project will, for the first time, provide conclusive evidence-based data on the WHO recommendation to treat kala-azar/HIV co-infected patients using Ambisome 40 mg/kg total dose, and on the locally used regimen of AmBisome 30mg/kg in combination with miltefosine that is used by MSF in Ethiopia. To do this, AfriCoLeish has the right partners all focused on a clear goal: neglected patients' needs', she added.

AfriCoLeish brings together six well-respected organizations from Europe and East Africa with vast experience in R&D and treatment of HIV and kala-azar, namely the Drugs for Neglected Diseases initiative (DNDi); the Institute of Tropical Medicine (ITM) in Antwerp; the London School of Hygiene & Tropical Medicine; Mdecins Sans Frontires (MSF, The Netherlands); the Institute of Endemic Diseases, University of Khartoum (IEND), Sudan; and the University of Gondar (UoG), Ethiopia.

'We are convinced that AfriCoLeish combines the experience and expertise required to deliver new treatment options that effectively address the dire needs of patients with kala-azar and those co-infected with kala-azar and HIV in our countries', said Dr Ermias Diro, Medical Coordinator, University of Gondar, Ethiopia. 'At the same time, the project will contribute to strengthening capacities in our treatment centres', he added.

The dissemination of AfriCoLeish project results will facilitate uptake of new treatments for kala-azar and for co-infection of kala-azar with HIV in East Africa, and will provide support to national programmes in the adoption of the new treatments. The improved treatment options will allow patients in East Africa to benefit from safe, cost-effective, and shorter treatments, while also reducing the treatment costs for health providers.


Contact: Violaine Dällenbach
Drugs for Neglected Diseases Initiative

Related medicine news :

1. Hasbro Childrens Hospital physician receives $3.2 million grant to study teen alcohol use
2. AmeriPride Minneapolis Receives ‘Hygienically Clean Healthcare’ Certification from the Textile Rental Services Association (TRSA)
3. Dr. Sam Speron Receives the 2012 America’s Most Compassionate Doctor Award
4. Morelli receives AACR fellowship for research in metastatic colorectal cancer
5. Christopher Jayne, M.D., Receives InTone Specialist Certification To Treat Female Urinary Incontinence From InControl Medical, LLC
6. Local Female Clinical Research Executive Receives Industry Distinction as an Innovator for Change
7. Tosh Patterson Receives Honors at the 5th Annual Get RADICAL Women’s Conference Featuring Jillian Michaels, Lisa Nichols, Giuliana Rancic
8. Vincent R. Lucente, MD, MBA, Miles Murphy, MD, Nina Bhatia, MD, and Valerie Schissler, MSN, CRNP, Receives InTone Specialist Certification
9. Advanced Mold Diagnostics Receives Angie's List Super Service Award for 4th Straight Year
10. BU student receives 2013 Joanna M. Nicolay Melanoma Foundation scholarship award
11. UC Davis MIND Institute receives prestigious Autism Centers of Excellence Award
Post Your Comments:
(Date:11/27/2015)... , ... November 27, 2015 , ... CBD College ... of Allied Health Education Programs (CAAHEP) awarded accreditation to its Diagnostic Medical Sonography program. ... accredited colleges, as only one of twelve colleges and universities in the state of ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage Rock Posters, ... posters. This is one of Joplin's most famous and beautiful concert posters. The concert ... Michigan in Ann Arbor. The According to Hawley, "It is hard to believe that ...
(Date:11/26/2015)... ... 26, 2015 , ... Inevitably when people think Thanksgiving, they also think Holiday ... the Black Friday and Cyber Monday massage chair sales to receive the ... and low to find the best massage chair deals, they can see all of ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... to discuss bioavailability and the need to integrate dose form selection in early ... with OBN, the membership organization supporting and bringing together the UK’s emerging life ...
(Date:11/26/2015)... ... November 26, 2015 , ... WorldCare International, Inc., the ... 61st annual Employee Benefits Conference. The Employee Benefits Conference was hosted by the ... Wednesday, November 11th, 2015. The conference was held at the Hawaii Convention Center ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... THOUSAND OAKS, Calif. , Nov. 25, 2015 /PRNewswire/ ... of a Biologics License Application (BLA) with ... Administration (FDA) for ABP 501, a biosimilar candidate to ... the first adalimumab biosimilar application submitted to the FDA ... biosimilar pathway. Sean E. Harper , M.D., ...
(Date:11/25/2015)... AAIPharma Services Corp./Cambridge Major Laboratories, Inc. ... $15.8  Million to expand its laboratories and global ... The expansion will provide additional office space and ... of the pharmaceutical and biotechnology markets. ... up to 40,000 square feet of expanded development ...
(Date:11/25/2015)... Nov. 25, 2015  Henry Schein, Inc., the world,s ... office-based dental, medical and animal health practitioners, will unveil ... Henry Schein ConnectDental® Pavilion , which brings together ... open solutions designed to help any practice or laboratory ... for a schedule of experts appearing at the ...
Breaking Medicine Technology: